Patents by Inventor Ashley I. Bush

Ashley I. Bush has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180177839
    Abstract: The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Applicant: The Florey Institute of Neuroscience & Mental Health
    Inventors: Ashley I. Bush, David L. Copolov, Michael Berk
  • Publication number: 20100099762
    Abstract: The present invention relates generally to a method of treating a psychiatric or neuropsychiatric condition in a mammal with a combination therapy. More particularly, the present invention relates to a combination therapy comprising an antipsychotic agent and a compound that increases levels of glutathione in the body.
    Type: Application
    Filed: October 23, 2007
    Publication date: April 22, 2010
    Applicant: THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA
    Inventors: Ashley I. Bush, David L. Copolov, Michael Berk
  • Patent number: 7166472
    Abstract: Described are methods for the identification of agents useful in the treatment or prevention of cataracts. Also described are methods for the identification of agents that may inadvertently promote or accelerate the formation of cataracts, and methods of treating or preventing injuries to or diseases of the ocular lens, retina and/or macula. More specifically, the invention describes methods for the identification of pharmacological agents useful in treating cataracts by inhibiting the cross-linking of eye lens proteins.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: January 23, 2007
    Assignee: The General Hospital Corporation
    Inventors: Lee E. Goldstein, Ashley I. Bush
  • Patent number: 7045531
    Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, A?-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: May 16, 2006
    Assignee: The General Hospital Corporation
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Patent number: 6890727
    Abstract: The disclosed invention relates to assays for detecting and quantifying A? peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A? peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A? peptides from biological fluids are taught.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: May 10, 2005
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Ashley I. Bush, Robert D. Moir
  • Patent number: 6638711
    Abstract: The invention relates to methods for identifying candidate pharmacological agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathological conditions.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: October 28, 2003
    Assignee: The General Hospital Corporation
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Publication number: 20030073074
    Abstract: The disclosed invention relates to assays for detecting and quantifying A&bgr; peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A&bgr; peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A&bgr; peptides from biological fluids are taught.
    Type: Application
    Filed: October 25, 1999
    Publication date: April 17, 2003
    Inventors: RUDOLPH E. TANZI, ASHLEY I. BUSH, ROBERT D. MOIR
  • Publication number: 20020115223
    Abstract: The invention relates to rapid methods for determining formation of A&bgr; amyloid and screening compounds which inhibit formation of A&bgr; amyloid in vitro, as well as kits for carrying out the present methods. Such an agent used in vivo may prevent, ameliorate or reverse the symptoms of Alzheimer's disease and A&bgr; amyloidotic disorders related to Alzheimer's disease, Down's syndrome, and Guamanian amyotrophic lateral sclerosis/Parkinson's dementia complex. The process described in this invention involves the rapid induction of A&bgr; amyloid by a heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A&bgr;, such as zinc to form amyloid and determination of formation of tinctorial A&bgr; amyloid. Moreover, a method of determining effectiveness of a candidate anti-amyloidotic agent for prevention or treatment of A&bgr; amyloidosis is described which uses cell cultures which express at least a human A&bgr; peptide.
    Type: Application
    Filed: January 10, 2002
    Publication date: August 22, 2002
    Applicant: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Ashley I. Bush
  • Publication number: 20020084230
    Abstract: The present invention provides screening methods for identifying compounds which induce tardive dyskinesia (TD) when administered to an animal. In particular, the methods involve assaying for intermediates and end product of reactions associated with candidate compound mediated reduction of reducible substrates. Also provided are high-throughput screening methods for determining whether compounds induce TD when administered to an animal. Further, provided are methods for treating psychoses comprising testing antipsychotic drugs to identify those which will not induce TD when administered to an animal and administering one or more such drugs to a patient in need thereof.
    Type: Application
    Filed: October 5, 2001
    Publication date: July 4, 2002
    Inventors: Guochuan Tsai, Xudong Huang, Ashley I. Bush
  • Publication number: 20020082273
    Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions and compositions for treatment of conditions caused by amyloidosis, A&bgr;-mediated formation of ROS, or both, such as Alzheimer's disease, are disclosed.
    Type: Application
    Filed: September 21, 2001
    Publication date: June 27, 2002
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Patent number: 6365414
    Abstract: The invention relates to rapid methods for determining formation of A&bgr; amyloid and screening compounds which inhibit formation of A&bgr; amyloid in vitro, as well as kits for carrying out the present methods. Such an agent used in vivo may prevent, ameliorate or reverse the symptoms of Alzheimer's disease and A&bgr; amyloidotic disorders related to Alzheimer's disease, Down's syndrome, and Guamanian amyotrophic lateral sclerosis/Parkinson's dementia complex. The process described in this invention involves the rapid induction of A&bgr; amyloid by a heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A&bgr;, such as zinc to form amyloid and determination of formation of tinctorial A&bgr; amyloid. Moreover, a method of determining effectiveness of a candidate anti-amyloidotic agent for prevention or treatment of A&bgr; amyloidosis is described which uses cell cultures which express at least a human A&bgr; peptide.
    Type: Grant
    Filed: August 26, 1994
    Date of Patent: April 2, 2002
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Ashley I. Bush
  • Publication number: 20020025944
    Abstract: The invention relates to the identification of clioquinol as a pharmaceutically therapeutic agent for treatment of Alzheimer's disease and related pathological conditions.
    Type: Application
    Filed: October 10, 2001
    Publication date: February 28, 2002
    Inventors: Ashley I. Bush, Rudolph E. Tanzi, Mikhal Xilinas, Robert Cherny
  • Patent number: 6323218
    Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions and compositions for treatment of conditions caused by amyloidosis, A&bgr;-mediated formation of ROS, or both, such as Alzheimer's disease.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: November 27, 2001
    Assignee: The General Hospital Corporation
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Patent number: 6316269
    Abstract: The present invention provides screening methods for identifying compounds which induce tardive dyskinesia (TD) when administered to an animal. In particular, the methods involve assaying for intermediates and end products of reactions associated with candidate compound mediated reduction of reducible substrates. Also provided are high-throughput screening methods for determining whether compounds induce TD when administered to an animal. Further, provided are methods for treating psychoses comprising testing antipsychotic drugs to identify those which will not induce TD when administered to an animal and administering one or more such drugs to a patient in need thereof.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: November 13, 2001
    Assignee: The General Hospital Corporation
    Inventors: Guochuan Tsai, Xudong Huang, Ashley I. Bush
  • Patent number: 5972634
    Abstract: The disclosed invention relates to assays for detecting and quantifying A.beta. peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A.beta. peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A.beta. peptides from biological fluids are taught.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: October 26, 1999
    Assignee: The General Hospital Corporation
    Inventors: Rudolph E. Tanzi, Ashley I. Bush, Robert D. Moir